CatalystMarker
← board

GHRS

GH Research Ireland Limiteddistress 1/10 · well-funded / low risk
$28.30-1%today-3% from 52w high
ghres.com73 employeesFounded 2018Dublin, IrelandBiotechnology
Lead: Healthy Adult
Revenue
pre-revenue
Liquidity
$267M
Runway
6.1 yrs
Shares 1y
0%

Price & events

+69.1% over 6M
$13.03$21.08$29.13Jan 26Apr 26Jul 261.5Mdilution: EFFECT shelf_effective (2026-05-19)dilution: F-3 shelf_registration (2026-05-14)dilution: 424B5 offering (2026-05-14)dilution: 424B5 offering (2026-04-29)catalyst: PHASE1 5 Methoxy N,N Dimethyltryptamine (2026-05-01) — click to openrating: HC Wainwright & Co.: Buy (2026-05-19)rating: Cantor Fitzgerald: Overweight (2026-05-15)rating: Citizens: Market Outperform (2026-05-15)rating: Citizens: Market Outperform (2026-03-06)rating: Needham: Buy (2026-03-06)rating: HC Wainwright & Co.: Buy (2026-03-02)rating: RBC Capital: Outperform (2026-01-23)
CatalystRating changeDilutionFinancingdashed = today
-1.0%
1D
-2.8%
1W
+19.9%
1M
+50.5%
3M
+69.2%
6M
+98.7%
1Y
+137.2%
2Y
+63.5%
5Y
+47.0%
All

Overview

Market Cap
$1.76B
Volume
12.09K
52 Week Range
$11.80 – $29.13
Total Shares
62.03M
Float Shares
26.72M
Short %
7.21%
% Held by Insiders
24.23%
% Held by Institutions
70.22%
RVOL
0.04x
Beta
1.29

Pipeline stages · 1 programs

5 Methoxy N,N Dimethyltryptamine
Preclin
Ph1
Ph2
Ph3
Filed
PDUFA
Approved

Pipeline · 2 trials · 0 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
2026-05
Phase 15 Methoxy N,N DimethyltryptamineHealthy Adult12not yet recruiting
2025-02
Phase 15 Methoxy N,N DimethyltryptamineHealthy Volunteers52recruiting

Catalyst news & presentations · 1

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: 62,029,395 · 2 offerings/1y · 0 PIPEs
  • 2026-05-19EFFECTshelf_effective
  • 2026-05-14424B5offering
  • 2026-05-14F-3shelf_registration
  • 2026-04-29424B5offering
  • 2025-03-07EFFECTshelf_effective
  • 2025-02-27F-3shelf_registration
  • 2025-02-05424B5offering
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

strong buy · target $40 (+40% upside) · 8 analysts
  • 2026-05-19HC Wainwright & Co.Buy
  • 2026-05-15Cantor FitzgeraldOverweight
  • 2026-05-15CitizensMarket Outperform
  • 2026-03-06CitizensMarket Outperform
  • 2026-03-06NeedhamBuy
  • 2026-03-02HC Wainwright & Co.Buy

Competitors — Healthy Adult

  • PFEPFIZER INC$142.2B · D3
  • BEIGFBeOne Medicines Ltd.$31.7B · D1
  • EWTXEdgewise Therapeutics, Inc.$4.1B · D4

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.